CRDFCardiff OncologyFinished
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
Metastatic Colorectal Cancer · KRAS Gene Mutation
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 68 (final count)
- Started
- Jun 24, 2019
- Main results expected
- Jan 29, 2024
- Fully finished
- Jan 29, 2024
- Results posted
- Mar 4, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)
Measured over: Up to Day 28
Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Measured over: Up to a maximum of 81 weeks
All-Treated Analysis Set: Objective Response Rate (ORR)
Measured over: Up to a maximum of 131 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03829410 · record last updated 2025-03-04 · checked 2026-11-09 15:47 UTC